Evaxion A/S (NASDAQ:EVAX) vs. Phreesia (NYSE:PHR) Head to Head Comparison

Evaxion A/S (NASDAQ:EVAX) and Phreesia (NYSE:PHR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Valuation & Earnings

This table compares Evaxion A/S and Phreesia”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$3.34 million	15.91	-$10.57 million	($0.39)	-16.33
Phreesia	$419.81 million	2.26	-$58.53 million	($0.10)	-158.15

Evaxion A/S has higher earnings, but lower revenue than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Evaxion A/S and Phreesia, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1	0	3	1	2.80
Phreesia	1	0	16	1	2.94

Evaxion A/S currently has a consensus price target of $12.33, indicating a potential upside of 93.62%. Phreesia has a consensus price target of $31.13, indicating a potential upside of 96.81%. Given Phreesia’s stronger consensus rating and higher possible upside, analysts clearly believe Phreesia is more favorable than Evaxion A/S.

Insider & Institutional Ownership

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 5.5% of Phreesia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Evaxion A/S has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Profitability

This table compares Evaxion A/S and Phreesia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-68.82%	-24.12%
Phreesia	-1.16%	-1.36%	-0.96%

Summary

Phreesia beats Evaxion A/S on 9 of the 14 factors compared between the two stocks.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About Phreesia

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.